Rucaparib is named as a drug or biological intervention in 3 clinical trials in our USA, Ireland, UK and China trial registers, 1 of which is recruiting. Lead sponsors include Bristol-Myers Squibb (1), pharmaand GmbH (1) and Hoffmann-La Roche (1). Registered phases: Phase 3 and Phase 2. Conditions studied include Cancer; Epithelial Ovarian Cancer; Primary Peritoneal.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT03899155 | Pan Tumor Rollover Study Cancer |
Phase 2 | Recruiting |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ClinicalTrials.gov ↗) Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer |
Phase 3 | Active, closed |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (ClinicalTrials.gov ↗) Cancer |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Cancer | 2 |
| Epithelial Ovarian Cancer | 1 |
| Primary Peritoneal | 1 |
| Fallopian Tube Cancer | 1 |
| Newly Diagnosed | 1 |
| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 1 |
| pharmaand GmbH | 1 |
| Hoffmann-La Roche | 1 |
| Register | Rucaparib trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in Ireland | 2 |
| Clinical trials in UK | 2 |
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rucaparib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rucaparib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.